ArticleJCO precision oncology2025

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor-/Progesterone Receptor-Negative, Human Epidermal Growth Factor Receptor 2-Positive Refractory Metastatic Breast Cancer.

Spencer Gibson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.